JiangXi Tianxin Pharm Co Ltd (603235) - Net Assets
Based on the latest financial reports, JiangXi Tianxin Pharm Co Ltd (603235) has net assets worth CN¥4.68 Billion CNY (≈ $684.97 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.75 Billion ≈ $842.11 Million USD) and total liabilities (CN¥1.07 Billion ≈ $157.14 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check JiangXi Tianxin Pharm Co Ltd (603235) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.68 Billion |
| % of Total Assets | 81.34% |
| Annual Growth Rate | 41.39% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 44.44 |
JiangXi Tianxin Pharm Co Ltd - Net Assets Trend (2020–2024)
This chart illustrates how JiangXi Tianxin Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore JiangXi Tianxin Pharm Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for JiangXi Tianxin Pharm Co Ltd (2020–2024)
The table below shows the annual net assets of JiangXi Tianxin Pharm Co Ltd from 2020 to 2024. For live valuation and market cap data, see 603235 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.62 Billion ≈ $675.45 Million |
+9.05% |
| 2023-12-31 | CN¥4.23 Billion ≈ $619.41 Million |
+4.31% |
| 2022-12-31 | CN¥4.06 Billion ≈ $593.81 Million |
+112.60% |
| 2021-12-31 | CN¥1.91 Billion ≈ $279.30 Million |
+65.27% |
| 2020-12-31 | CN¥1.15 Billion ≈ $168.99 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to JiangXi Tianxin Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2420.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.02 Billion | 43.81% |
| Other Components | CN¥2.59 Billion | 56.19% |
| Total Equity | CN¥4.62 Billion | 100.00% |
JiangXi Tianxin Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of JiangXi Tianxin Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Microgate Technology Co Ltd
SHE:300319
|
$1.66 Billion |
|
Pexa Group Ltd
AU:PXA
|
$1.66 Billion |
|
Sionna Therapeutics, Inc. Common Stock
NASDAQ:SION
|
$1.66 Billion |
|
JHSF Participações S.A.
SA:JHSF3
|
$1.66 Billion |
|
Artivion Inc
NYSE:AORT
|
$1.66 Billion |
|
Luoyang Longhua Heat Trans Energy
SHE:300263
|
$1.66 Billion |
|
HBIS Resources Co Ltd
SHE:000923
|
$1.66 Billion |
|
Bangchak Corporation Public Company Limited
BK:BCP
|
$1.66 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in JiangXi Tianxin Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,232,947,161 to 4,615,885,977, a change of 382,938,816 (9.0%).
- Net income of 651,223,140 contributed positively to equity growth.
- Dividend payments of 220,188,547 reduced retained earnings.
- Other factors decreased equity by 48,095,777.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥651.22 Million | +14.11% |
| Dividends Paid | CN¥220.19 Million | -4.77% |
| Other Changes | CN¥-48.10 Million | -1.04% |
| Total Change | CN¥- | 9.05% |
Book Value vs Market Value Analysis
This analysis compares JiangXi Tianxin Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.46x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.85x to 2.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥2.93 | CN¥25.94 | x |
| 2021-12-31 | CN¥4.84 | CN¥25.94 | x |
| 2022-12-31 | CN¥9.27 | CN¥25.94 | x |
| 2023-12-31 | CN¥9.67 | CN¥25.94 | x |
| 2024-12-31 | CN¥10.54 | CN¥25.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently JiangXi Tianxin Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.11%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.49%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.21x
- Recent ROE (14.11%) is below the historical average (31.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 76.81% | 38.51% | 0.79x | 2.52x | CN¥771.60 Million |
| 2021 | 38.97% | 29.49% | 0.85x | 1.55x | CN¥553.02 Million |
| 2022 | 15.33% | 26.99% | 0.49x | 1.15x | CN¥216.32 Million |
| 2023 | 11.24% | 25.28% | 0.37x | 1.20x | CN¥52.56 Million |
| 2024 | 14.11% | 29.49% | 0.39x | 1.21x | CN¥189.63 Million |
Industry Comparison
This section compares JiangXi Tianxin Pharm Co Ltd's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $2,994,389,347
- Average return on equity (ROE) among peers: 11.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| JiangXi Tianxin Pharm Co Ltd (603235) | CN¥4.68 Billion | 76.81% | 0.23x | $1.66 Billion |
| Shenzhen Shenbao Industrial Co Ltd (000019) | $296.80 Million | 11.46% | 0.53x | $1.26 Billion |
| Hainan Pearl River Holdings Co Ltd (000505) | $585.78 Million | -31.84% | 1.22x | $648.05 Million |
| Xiwang Foodstuffs Co Ltd (000639) | $76.25 Million | 11.36% | 0.86x | $304.85 Million |
| Nanfang Black Sesame Group Co Ltd (000716) | $2.71 Billion | 2.87% | 0.70x | $570.04 Million |
| CNFC Overseas Fishery Co Ltd (000798) | $256.68 Million | 54.64% | 0.92x | $499.50 Million |
| Henan Shuanghui Investment & Development Co Ltd (000895) | $23.15 Billion | 21.02% | 0.47x | $14.05 Billion |
| Xinjiang Chalkis Co Ltd (000972) | $628.09 Million | 8.48% | 2.86x | $440.17 Million |
| Zhengzhou Qianweiyangchu Food Co Ltd (001215) | $1.82 Billion | 4.59% | 0.27x | $687.56 Million |
| Qingdao Foods Co Ltd (001219) | $299.34 Million | 12.12% | 0.20x | $447.10 Million |
| Shandong Oriental Ocean Sci-Tech Co Ltd (002086) | $117.09 Million | 24.08% | 1.95x | $584.78 Million |
About JiangXi Tianxin Pharm Co Ltd
JiangXi Tianxin Pharmaceutical Co., Ltd. produces and sells vitamins in China. The company offers products of vitamin B6, vitamin B1, Vitamin D3, pyridoxine hydrochloride CD grade, thiamine nitrate DC grade, folic acid, biotin, ascorbyl palmitate, vitamin E 500, a-acetyl-"-butyrolactone, and vitamin D3 for use as bulk pharmaceutical chemicals, API, food additives, and feed additives, as well as i… Read more